FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product
FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug.
FDA cited claims that the product was a “Desert Herbs Formula for Prostate & Testicules [sic] Cancers” and was promoted for patients with prostate cancer, testicular malignancies, and other severe male reproductive conditions.
The agency also cited claims describing anticancer, antiproliferative, anti-metastatic, and selective cytotoxic effects, including statements that the product could inhibit uncontrolled cell division, prevent spread of malignant cells, and act against multiple cancer types.
FDA concluded that these claims established the product’s intended use as a drug. Because no approved FDA application was in effect for the product, FDA determined it was an unapproved new drug.
The firm was instructed to respond within 15 business days with corrective steps and measures to prevent recurrence.
MDP Perspective
This warning letter involves some of the highest-risk claim language in FDA enforcement: cancer treatment claims.
FDA has consistently treated cancer-related claims as a serious public health concern because patients may delay or avoid evidence-based medical care in favor of unapproved products.
For herbal, natural, supplement, and wellness companies, this letter is a clear warning. Claims involving cancer, metastasis, apoptosis, cytotoxicity, or disease treatment are not casual marketing language. They can create drug status immediately and invite FDA enforcement.
Links
Warning letter to Leading Edge Health, Inc.
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...
FDA Moves Toward New Peptide Compounding Policy
FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Early Alert for Baxter Intravascular Administration Sets
Healthcare facilities are instructed to immediately stop using affected IV solution sets while FDA evaluates the potentially high-risk device issueThe U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Baxter Duo-Vent Solution Sets...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
